Adoptive cellular therapy is an immunotherapy that isolates and uses specific immune cells to fight cancer. It is also known as T-cell transfer therapy, adoptive immunotherapy or immune cell therapy. During these therapies, your care team multiplies or modifies immune cells in the lab and infuses them into your body to help your immune system work more effectively.
Different adoptive cellular therapies work in various cancer types. For example, CAR T-cell therapy is approved to treat blood cancer, while TIL therapy treats advanced melanoma.
Tumor-infiltrating lymphocyte (TIL) therapy
Tumor-infiltrating lymphocyte (TIL) therapy improves the ability of your own TIL cells to fight cancer. These immune cells constantly move through your body and look for abnormal cells. When activated, they go from your blood into a tumor to kill cancer cells. But sometimes, they don’t work as they should, or your body doesn’t have enough TIL cells to fight off cancer effectively.
To boost the ability of TIL cells in your body, these cells can be taken from your body and activated and multiplied in the lab. Then, millions of cancer-fighting TIL cells are infused back into your blood to boost your immune system’s ability to destroy cancer.
Currently, TIL therapy is only approved by the Food and Drug Administration for people with advanced melanoma.
Chimeric antigen receptor T-cell therapy (CAR-T)
Chimeric antigen receptor T-cell therapy (CAR-T) is a form of immunotherapy that uses T cells to fight cancer.
T cells naturally work in your body to find and attack cancer cells. To do this, they have proteins called receptors. These receptors bind to proteins called antigens on the surface of cancer cells to help your body destroy them. But sometimes, T cells can’t recognize the antigens on cancer cells.
To give your T cells the receptors they need, doctors take T cells from your blood, add a synthetic receptor called a chimeric antigen receptor (CAR) in the lab, and multiply these modified T cells. The new CAR-T cells are then infused back into your body to target specific antigens on the surface of cancer cells.
CAR T-cell therapy is currently approved by the FDA to treat some types of blood cancer, including leukemia, lymphoma and multiple myeloma.
T cell receptor (TCR) therapy
Sometimes, T cells cannot recognize the cancer cells in your body. Like CAR-T therapy, T cell receptor (TCR) therapy modifies your own T cells to help them better identify and target cancer cells. But TCR therapy targets different antigens on cancer cells.
During TCR therapy, your T cells are modified and multiplied in the lab. Doctors can choose the specific target and type of T cell to change, allowing your team to make this therapy work for your cancer. TCR therapy is being studied in a range of cancer types, including blood cancers and solid tumors.
Chimeric antigen receptor (CAR) natural killer (NK) cell therapy
Most immunotherapies use the power of your T cells to fight cancer. But some therapies are being developed using other types of immune cells, including natural killer (NK) cells. NK cells look for and attack many types of abnormal cells in the body.
During chimeric antigen receptor (CAR) NK natural killer (NK) cell therapy, NK cells are multiplied or modified in the lab. Then, they are infused into your body, where they can better attack cancer cells. Unlike T cell therapies, NK cell therapy doesn’t require using your own cells.